These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29146518)

  • 21. [A "new" mechanism behind the hypersensitive reactions to drug combinations. A report from a meeting].
    Naess K
    Tidsskr Nor Laegeforen; 1973 Jan; 93(3):183-4. PubMed ID: 4693379
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular therapeutics from knowledge to delivery.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2010 Jun; 87(6):619-23. PubMed ID: 20485312
    [No Abstract]   [Full Text] [Related]  

  • 23. [How to reduce iatropathology in elderly patients].
    Bouchon JP
    Rev Prat; 1990 May; 40(15):1371-4. PubMed ID: 2356426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks?
    Watts PJ; Smith A
    Drug Discov Today; 2011 Jan; 16(1-2):4-7. PubMed ID: 21074635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 26. A new paradigm for improving oral absorption of drugs in discovery: role of physicochemical properties, different excipients and the pharmaceutical scientist.
    Wilson AG; Nouraldeen A; Gopinathan S
    Future Med Chem; 2010 Jan; 2(1):1-5. PubMed ID: 21426039
    [No Abstract]   [Full Text] [Related]  

  • 27. Defining the future of pharmacometrics: the American Society of Pharmacometrics.
    Pfister M; Brundage RC; Gastonguay MR; Miller R; Tannenbaum SJ; D'Argenio DZ
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):158S. PubMed ID: 20881230
    [No Abstract]   [Full Text] [Related]  

  • 28. Formulation and Delivery of Macromolecules.
    Morales JO
    AAPS PharmSciTech; 2017 Jan; 18(1):1-2. PubMed ID: 27943123
    [No Abstract]   [Full Text] [Related]  

  • 29. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in inkjet dispensing technologies: applications in drug discovery.
    Zhu X; Zheng Q; Yang H; Cai J; Huang L; Duan Y; Xu Z; Cen P
    Expert Opin Drug Discov; 2012 Sep; 7(9):761-70. PubMed ID: 22724503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico assessment of adverse drug reactions and associated mechanisms.
    Ivanov SM; Lagunin AA; Poroikov VV
    Drug Discov Today; 2016 Jan; 21(1):58-71. PubMed ID: 26272036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):127-34. PubMed ID: 26174631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From fragment to clinical candidate--a historical perspective.
    Chessari G; Woodhead AJ
    Drug Discov Today; 2009 Jul; 14(13-14):668-75. PubMed ID: 19427404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 37. Raman spectroscopy in pharmaceutical product design.
    Paudel A; Raijada D; Rantanen J
    Adv Drug Deliv Rev; 2015 Jul; 89():3-20. PubMed ID: 25868453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Physicochemical incompatibilities of injectable drugs].
    Hoffman M; Hazebroucq G
    Sem Hop; 1983 Feb; 59(8):541-7. PubMed ID: 6302899
    [No Abstract]   [Full Text] [Related]  

  • 39. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drugs for rectal administration (a review of the literature)].
    Golovkin VA; Peshekhonova LL; Lukash EP
    Vrach Delo; 1984 Nov; (11):7-11. PubMed ID: 6396948
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.